Physician profile
Alan Bierlein
NPI 1063493997
$20,644.48
in general payments reported to CMS, 2019-2025
57 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,280 · 2020: $2,696 · 2021: $5,665 · 2022: $5,126 · 2023: $2,878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,878.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,998.88 | 2019-2023 | Otezla, Repatha |
| Lilly USA, LLC | $1,827.21 | 2019-2023 | Mounjaro, Trulicity, Jardiance |
| Abbvie INC. | $1,703.46 | 2021-2023 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $1,624.84 | 2019-2023 | Farxiga, Breztri |
| Novo Nordisk INC | $1,150.10 | 2019-2023 | Ozempic, Rybelsus |
| Esperion Therapeutics, INC. | $1,069.71 | 2020-2022 | |
| Pfizer INC. | $1,015.07 | 2019-2023 | |
| Glaxosmithkline, LLC. | $819.83 | 2019-2023 | Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $720.86 | 2019-2023 | Austedo, Ajovy, Uzedy |
| Bayer Healthcare Pharmaceuticals INC. | $691.61 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $657.48 | 2021 | |
| Janssen Pharmaceuticals, INC | $551.32 | 2019-2021 | |
| Allergan, INC. | $535.83 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $449.70 | 2019-2023 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $415.86 | 2019-2023 | Trintellix |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Bierlein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.